-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the news of layoffs in 116 pharmaceutical companies in the past year has caused heated discussions in the indust.
At the same time, the new salary situation of pharmaceutical workers has also attracted everyone's attenti.
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 17% from 149,300 yuan in 202 Specifically, there are 12 pharmaceutical companies with an average annual salary of over 400,000 yuan; a total of 359 companies ranging from 100,000 to 400,000 yuan; in addition, 60 companies have an average annual salary of less than 100,000 yu.
From the perspective of per capita salary increases, four pharmaceutical companies have doubled their increases, namely Rejing Bio, Oriental Bio, Jingfeng Pharmaceutical and Guizhou San.
These four companies are mainly involved in epidemic-related businesses such as nucleic acid reagents, traditional Chinese medicine, and mas.
From the performance point of view, the annual performance report released by Rejing Biology on April 28 stated that the operating income in 2021 will be about 369 billion yuan, a year-on-year increase of 9454%; the net profit attributable to shareholders of the listed company is about 186 billion yuan, a year-on-year increase of 1854 %; basic earnings per share was 314 yuan, a year-on-year increase of 1852
It is proposed to distribute a cash dividend of 50 yuan (tax included) for every 10 shares, and no bonus shares will be distribut.
The company's main business is in vitro diagnostic reagents and instrumen.
In 2021, Orient Bio will achieve operating income of 1169 billion yuan, a year-on-year increase of 2143%, net profit of 920 billion yuan, a year-on-year increase of 1933%, and basic earnings per share of 400 yu.
During the reporting period, the company's in vitro diagnostic business contributed most of its revenue, achieving revenue of 1152 billion yuan, a year-on-year increase of 219
Jingfeng Pharmaceutical is expected to reduce losses in 2021, with an estimated operating income of 700 million to 000 billion yuan, net profit attributable to shareholders of listed companies of -220 million to -190 million yuan, and net profit increased by 741% to 822% year-on-ye.
The stock income is -25 to -21 yu.
The company is involved in drug research and development, production, sales and other businesses, and in the field of pharmaceutical investme.
Guizhou Sanli will achieve a revenue of 944 million yuan in 2021, a year-on-year increase of 477%; the net profit attributable to shareholders of the listed company is 185 million yuan, a year-on-year increase of 68
The company is a domestic manufacturer of oral and throat sprays for childr.
The main reason for the change in performance in 2021 is that the market demand for the company's main products has recovered and achieved grow.
At the same time, Sanli Zhongyue, a wholly-owned subsidiary, has further improved the company's product sales coverage by providing professional marketing planning and promotion services, and the development and construction of the second and third terminal channels have achieved initial resul.
However, for the business related to the epidemic, some companies have also experienced a reduction in the per capita annual salary, such as Shengxiang Bio, Zhijiang Bio, BGI, and Nanw.
Among them, the per capita salary of Shengxiang Bio’s employees will drop from 361,500 yuan in 2020 to 173,500 yuan in 2021, and the per capita annual salary of BGI will reach 507,300 yuan in 2020, but it will drop to 285,800 yuan in 202 In addition, the per capita annual salary of Nanwei and Zhijiang Bio decreased by 416% and 216% respective.
From the perspective of the reasons, the analysis pointed out that although the performance of these four companies in 2021 has increased, due to the surge in the total business volume, the company has greatly recruited people, resulting in a sharp drop in per capita sala.
For those companies that achieve per capita salary growth in 2021, whether this year can continue, the industry believes that it is still uncerta.
However, the salary level is somewhat linked to performan.
Judging from the performance of the first quarter of 2022, there are still many companies that maintain high growth, such as Oriental B.
Click to enter the exhibition page
At the same time, the new salary situation of pharmaceutical workers has also attracted everyone's attenti.
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 17% from 149,300 yuan in 202 Specifically, there are 12 pharmaceutical companies with an average annual salary of over 400,000 yuan; a total of 359 companies ranging from 100,000 to 400,000 yuan; in addition, 60 companies have an average annual salary of less than 100,000 yu.
From the perspective of per capita salary increases, four pharmaceutical companies have doubled their increases, namely Rejing Bio, Oriental Bio, Jingfeng Pharmaceutical and Guizhou San.
These four companies are mainly involved in epidemic-related businesses such as nucleic acid reagents, traditional Chinese medicine, and mas.
From the performance point of view, the annual performance report released by Rejing Biology on April 28 stated that the operating income in 2021 will be about 369 billion yuan, a year-on-year increase of 9454%; the net profit attributable to shareholders of the listed company is about 186 billion yuan, a year-on-year increase of 1854 %; basic earnings per share was 314 yuan, a year-on-year increase of 1852
It is proposed to distribute a cash dividend of 50 yuan (tax included) for every 10 shares, and no bonus shares will be distribut.
The company's main business is in vitro diagnostic reagents and instrumen.
In 2021, Orient Bio will achieve operating income of 1169 billion yuan, a year-on-year increase of 2143%, net profit of 920 billion yuan, a year-on-year increase of 1933%, and basic earnings per share of 400 yu.
During the reporting period, the company's in vitro diagnostic business contributed most of its revenue, achieving revenue of 1152 billion yuan, a year-on-year increase of 219
Jingfeng Pharmaceutical is expected to reduce losses in 2021, with an estimated operating income of 700 million to 000 billion yuan, net profit attributable to shareholders of listed companies of -220 million to -190 million yuan, and net profit increased by 741% to 822% year-on-ye.
The stock income is -25 to -21 yu.
The company is involved in drug research and development, production, sales and other businesses, and in the field of pharmaceutical investme.
Guizhou Sanli will achieve a revenue of 944 million yuan in 2021, a year-on-year increase of 477%; the net profit attributable to shareholders of the listed company is 185 million yuan, a year-on-year increase of 68
The company is a domestic manufacturer of oral and throat sprays for childr.
The main reason for the change in performance in 2021 is that the market demand for the company's main products has recovered and achieved grow.
At the same time, Sanli Zhongyue, a wholly-owned subsidiary, has further improved the company's product sales coverage by providing professional marketing planning and promotion services, and the development and construction of the second and third terminal channels have achieved initial resul.
However, for the business related to the epidemic, some companies have also experienced a reduction in the per capita annual salary, such as Shengxiang Bio, Zhijiang Bio, BGI, and Nanw.
Among them, the per capita salary of Shengxiang Bio’s employees will drop from 361,500 yuan in 2020 to 173,500 yuan in 2021, and the per capita annual salary of BGI will reach 507,300 yuan in 2020, but it will drop to 285,800 yuan in 202 In addition, the per capita annual salary of Nanwei and Zhijiang Bio decreased by 416% and 216% respective.
From the perspective of the reasons, the analysis pointed out that although the performance of these four companies in 2021 has increased, due to the surge in the total business volume, the company has greatly recruited people, resulting in a sharp drop in per capita sala.
For those companies that achieve per capita salary growth in 2021, whether this year can continue, the industry believes that it is still uncerta.
However, the salary level is somewhat linked to performan.
Judging from the performance of the first quarter of 2022, there are still many companies that maintain high growth, such as Oriental B.
Click to enter the exhibition page
